SlideShare a Scribd company logo
1 of 42
Download to read offline
“Pros and cons of prostate 
cancer screening” . 
Mungai Ngugi 
Director East African kidney institute 
University of Nairobi
Introduction 
DEFINITION early detection and screening for prostate cancer 
• detection of disease at an early, pre-symptomatic stage 
• The man would have no reason to seek medical care – 
• The intervention is referred to as secondary prevention 
• Distinct from detection of prostate cancer in symptomatic men,
Introduction 
• Population or mass screening is defined as the examination of 
asymptomatic men (at risk). 
• It usually takes place as part of a trial or study and is initiated by the 
screener. 
• In contrast, early detection or opportunistic screening comprises 
individual case findings, which are initiated by the person being 
screened (patient) and/or his physician
introduction 
• Prostate cancer mortality trends range widely from country to 
country in the industrialised world . 
• Decreased mortality rates due to PCa have occurred in the USA, 
Austria, UK, and France, while in Sweden the 5-year survival rate has 
increased from 1960 to 1988, probably due to increased diagnostic 
activity and greater detection of non-lethal tumours .
introduction 
• The primary endpoint of both types of screening has two aspects: 
• 1.Reduction in mortality from PCa. The goal is not to detect more 
carcinomas, nor is survival the endpoint because survival is strongly 
influenced by lead-time from diagnosis. 
• 2.The quality of life is important as expressed by quality-of-life 
adjusted gain in life years.
introduction 
The reduced mortality seen recently in the USA is often attributed to 
the widely adopted aggressive screening policy, but there is still no 
absolute proof that prostate-specific antigen (PSA) screening reduces 
mortality due to PCa
U.S. Preventive Services Task Force (USPSTF): 
• Although the USPSTF DISCOURAGES the use of screening tests for 
which the benefits do not outweigh the harms in the target 
population, it recognizes the common use of PSA screening in practice 
today and understands that some men will continue to request 
screening and some physicians will continue to offer it
Potential Harms Related to Screening and 
Diagnostic Procedures 
• Convincing evidence demonstrates that the prostate-specific antigen 
(PSA) test often produces false-positive results 
• approximately 80% of positive PSA test results are false-positive when 
cut offs between 2.5 and 4.0 μg/L are used. 
• There is adequate evidence that false-positive PSA test results are 
associated with negative psychological effects, including persistent 
worry about prostate cancer 
• Men who have a false-positive test result are more likely to have 
additional testing, including 1 or more biopsies, in the following year 
than those who have a negative test result
Harm USPSTF 
• one third of men who have prostate biopsy experience pain, fever, 
bleeding, infection, transient urinary difficulties, or other issues 
requiring clinician follow-up that the men consider a "moderate or 
major problem"; 
• approximately 1% require hospitalization.
Harms Related to Treatment of Screen- 
Detected Cancer USPSTF 
• 90% of men with PSA-detected prostate cancer in the United States 
have early treatment with surgery, radiation, or androgen deprivation 
therapy 
• evidence shows that up to 5 in 1000 men will die within 1 month of 
prostate cancer surgery and between 10 and 70 men will have serious 
complications but survive. 
• Radiotherapy and surgery result in long-term adverse effects, 
including urinary incontinence and erectile dysfunction in at least 200 
to 300 of 1000 men treated with these therapies. 
• Radiotherapy is also associated with bowel dysfunction.
Harms Related to Treatment of Screen- 
Detected Cancer USPSTF 
• evidence shows that androgen deprivation therapy for localized 
prostate cancer is associated with erectile dysfunction (in 
approximately 400 of 1000 men treated), as well as gynecomastia and 
hot flashes.
AUA 
• recommends against PSA screening in men under age 40 years. 
• does not recommend routine screening in men between ages 40 to 
54 years at average risk 
• For ages 55 to 69 years the decision to undergo PSA screening 
involves weighing the benefits of preventing prostate cancer mortality 
in 1 man for every 1,000 men screened over a decade against the 
known potential harms associated with screening and treatment. 
• strongly recommends shared decision-making for men age 55 to 69 
years that are considering PSA screening, and proceeding based on a 
man's values and preferences
SCREENING 
• To reduce the harms of screening, a routine screening interval of two 
years or more may be preferred over annual screening in those men 
who have participated in shared decision-making and decided on 
screening. As compared to annual screening, it is expected that 
screening intervals of two years preserve the majority of the benefits 
and reduce overdiagnosis and false positives
AUA 
• Since the advent of PSA screening, the incidence of patients 
presenting with advanced prostate cancer has declined remarkably 
and death rates from prostate cancer as reported in the National 
Cancer Database have declined at the rate of 1% per year since 1990. 
• Other data indicate similar declines in prostate cancer related 
mortality in the US. 
• THE DEGREE TO WHICH THIS IS ATTRIBUTABLE TO PSA SCREENING IS 
HIGHLY CONTROVERSIAL EVEN THOUGH IT IS TEMPORALLY LINKED 
WITH THE INTRODUCTION OF PSA-BASED SCREENING.
AUA 
• does not recommend routine PSA screening in men age 70+ years or 
any man with less than a 10 to 15 year life expectancy 
• recommends against PSA screening in men under age 40 years. 
• In this age group there is a low prevalence of clinically detectable 
prostate cancer 
• no evidence demonstrating benefit of screening in <40 and there is 
likelihood of the same harms of screening as in other age groups. 
• does not recommend routine screening in men between ages 40 to 
54 years at average risk of prostate cancer
AUA guidelines 
• recommends screening with limited confidence in the target group 
age 55 to 69 years 
• This age range represents the group with the highest quality evidence 
of benefit. 
• There is potential for harm, and for this reason recommends shared 
decision making prior to screening decisions 
• The AUA used as evidence six trials-Stockholm, Norrkoping, Quebec, 
ERSPC, Goteborg and PLCO trials 
• The trials included men age 45 to 80 years, but only the Quebec trial 
informs about men below age 50 and above age 74 years.
PSA 
• None of the studies were designed to estimate if PSA screening 
influences overall mortality
AUA guidelines 
• For men younger than age 55 years at higher risk (e.g. positive family 
history or African American race), decisions regarding prostate cancer 
screening should be individualized. 
• For men ages 55 to 69 years the decision to undergo PSA screening 
involves weighing the benefits of preventing prostate cancer mortality 
in 1 man for every 1,000 men screened over a decade against the 
known potential harms associated with screening and treatment. 
• AUA recommends shared decision-making for men age 55 to 69 years 
that are considering PSA screening, and proceeding based on a man's 
values and preferences
AUA guidelines 
• To reduce the harms of screening, a routine screening interval of two 
years or more may be preferred over annual screening in those men 
who have participated in shared decision-making and decided on 
screening. 
• screening intervals of two years preserve the majority of the benefits 
and reduces overdiagnosis and false positives 
• Does not recommend routine PSA screening in men age 70+ years or 
any man with less than a 10 to 15 year life expectancy
Mortality outcomes 
Prostate cancer mortality sourrce Relative risk Absolute effect 
1RCT ERSPC 
162243 
Age 55-69 psa every four 
years 
0.8(0.65-0.98) 1 death /1000 men 
screaned 
1 rctPCLO 79693 
Age 55-74 annual PSA 
screaning for 6 yrs and 
DRE annually for four ysa 
1.14(0.76-1.70) >1 death -1 death -1 
death per 1000 men 
sreaned
Harm outcome 
Minor (hematuria/ 
hematospermia) 
20-50% 20-50% (first time sextant 
biopsy, Netherland site, 
ERSPC) 
24-45% (ERSPC, 
Rotterdam) 
Composite medical 
complications (infection, 
bleeding, urinary 
difficulties) 
68/10,000 PLCO33
Harm outcome false positive 
Adverse event estimate Data source evidence 
False +ve tests 75.9% Proportion of men 
psa>3ngms/ml and no 
cancer on subsequent 
biopsy ESPRC 
Moderate to high 
12% Cummulative risk of at 
least 1 false positive after 
four rounds of testing 
every 4 years ERSPC 
13% risk of undergoing at 
least 1 +positive biopsy 
(psa>4) after four rounds 
of annual testing PCLO 
5.5% Risk of undergoing
Harm outcome -overdiagnosis 
66% Cases overdiagnosed as a 
fraction of screan 
detected cases ESRPC 
23-42% Cases overdiagnosed as a 
fraction of screan 
detected cases SEER-9 
1987-2000
Harm outcome leadtime 
5.4-6.9 years Average time by which screaning 
advances diagnosis among cases 
who would have been diagnosed 
during their lifetime in the absence 
of screaning
screening 
• Introduction of PSA-based prostate cancer screening was followed by 
subsequent dramatic reductions in prostate cancer mortality. 
• in the US following the introduction of widespread PSA screening in 
the late 1980's, there ensued a ~70% increase in prostate cancer 
incidence. 
• Despite steadily rising prostate cancer mortality throughout the 
1970s and 1980s, several years after the introduction of PSA 
screening, mortality rates began to decline. 
• By 2008, mortality rates had fallen nearly 40% relative to their highs 
in the early 1990s 
Siegel R, Naishadham D and Jemal A: Cancer 
statistics, 2012. CA Cancer J Clin 2012; 62: 10.
US vs uk 
• In the US PSA screening became widespread in the late 1980s and 
early 1990s. 
• PSA screening was rarely performed in the UK and to this day 
remains lower than 10% of the population. 
• Prostate cancer death rates in the US began to decline in the early 
1990s and by 2009 had dropped by more than 40% since their peak in 
the early 1990s 
• The peak in incidence in the US was followed by a decline (36%) in 
mortality starting several years later 
Collin SM, Martin RM, Metcalfe C et al: Prostate-cancer 
mortality in the USA and UK in 1975-2004: an ecological study. 
Lancet Oncol 2008; 9: 445.
US vs UK 
• Though mortality rates also declined in the UK, the decline was much 
more modest (only 12%). Indeed, since 1994 prostate cancer 
mortality rates have declined four times faster in the US compared to 
the UK 
Howlader N, Noone AM, Krapcho M et al: SEER 
Cancer Statistics Review, 1975-2009 (Vintage 2009 
Populations), National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2009_pops09/, based on 
November 2011 SEER data submission, posted to the SEER web
psa 
• Almost all of the randomized studies that have evaluated PSA based 
screening for prostate cancer have demonstrated a benefit in terms of 
lower stage and grade of cancer at diagnosis. 
• Several studies have also revealed a significant reduction in prostate 
cancer specific mortality rates attributable to PSA based screening for 
prostate cancer
psa 
• PSA screening yields survival benefits that have contributed, to some 
extent, to the dramatic and sustained drop in prostate cancer death 
rates in the USA. 
• Second, PSA screening advances prostate cancer diagnosis by five to 
six years on average.
Psa 
• Approximately one in four screen-detected cases reflects 
overdiagnosis. 
• Strategies that screen less frequently than every year, and even less 
frequently for men with low PSA levels, are likely to be of value in 
reducing costs and harms while preserving most of the potential 
benefit of PSA-based screening
Psa developed countries 
• Since the advent of PSA screening, the incidence of patients 
presenting with advanced prostate cancer has declined remarkably 
and death rates from prostate cancer as reported in the National 
Cancer Database have declined at the rate of 1% per year since 1990. 
• Other data indicate similar declines in prostate cancer related 
mortality in the US. 
• The degree to which this is attributable to PSA screening is highly 
controversial even though it is temporally linked with the introduction 
of PSA-based screening
Increasing the ratio of benefit to harm 
• Screening for cancer in asymptomatic individuals, including prostate 
cancer, involves a tradeoff of benefit and harm 
• Through a decade, the absolute benefits of prostate cancer screening 
are modest for men age 55 to 69 years, and the harms are 
substantial 
• Over a lifetime the benefits increase but so do the harms. 
• The ratio of benefit to harm can be improved by looking at the health 
and age status of the individual and his preferences
Increacing benefit of screening 
• The strongest evidence of benefit for PSA screening for early 
diagnosis of prostate cancer is in the age group 55 to 69 years17 since 
this is the group studied in randomized trials 
• Thus, targeting of men age 55 to 69 years, after a risk benefit 
discussion, represents one approach to screening that is based on 
best evidence
<40 years 
• For men below age 40 years, AUA recommends against PSA-based 
screening. 
• The low prevalence of disease in men below age 40 years means that 
even in the best case of screening benefit in this age group, the 
incremental number of lives save by screening this age group is likely 
to be very small
40-54yrs 
• Men age 40 to 54 years often undergo PSA-based screening. However, 
as compared to initiating screening at age 50 years, it was estimated 
that screening beginning at age 40 years would result in the 
prevention of <1 prostate cancer death per 1,000 men. 
• Given that 99% of deaths from prostate cancer occur above age 54 
years, the screening average risk men below age 55 years should not 
be routine. 
Howard K, Barratt A, Mann GJ et al: A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to 
support informed choices. Arch Intern Med 2009; 169: 1603.
<55 
• For men younger than age 55 years at higher risk (e.g. positive family 
history or African American race), decisions regarding prostate cancer 
screening should be individualized based on personal preferences and 
an informed discussion regarding the uncertainty of benefit and the 
associated harms of screening.
>70yrs 
• Men age 70+ years have a high prevalence of prostate cancer but also 
have a greater risk of competing diseases and overdiagnosis when 
compared to younger men 
• ERSPC randomized trial of screening, there was no indication for a 
mortality reduction among men age 70 years or older by psa 
screening 
• given the lack of direct evidence for a benefit of screening beyond age 
70 years, and especially beyond age 74 years, routine screening in this 
age group is dicouraged 
Albertsen PC, Moore DF, Shih W et al: Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 133594, 
Schroder FH, Hugosson J, Roobol MJ et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981.
Fit men 
• Some men with high risk aggressive prostate cancers with a life 
expectancy less than a decade, may benefit from the diagnosis and 
treatment of their disease. Thus, the goal should be to identify these 
men while avoiding the associated overdiagnosis and over treatment 
of those with lower risk disease that occurs with opportunistic 
screening 
Wilt TJ, Brawer MK, Jones KM et al: Prostate Cancer 
Intervention versus Observation Trial (PIVOT) Study Group. 
Radical prostatectomy versus observation for localized prostate 
cancer. N Engl J Med 2012; 367: 203.
Testing Frequency 
• There is evidence to suggest that annual screening is not likely to 
produce significant incremental benefits when compared with an 
inter-screening interval of two years 
• The PLCO trial compared annual screening with opportunistic 
screening in the US population, which corresponded to screening on 
average every two years. 
• Prostate cancer mortality rates were similar in the two groups 
through 13 years of follow-up. 
20
Biopsy Trigger 
• There is no PSA level below which a man can be informed that 
prostate cancer does not exist. 
• the risk of prostate cancer, and that of high grade disease, is 
continuous as PSA increases 
• In the intervention (screened) arm of the ERSPC randomized 
screening trial, a PSA trigger of 3ng/mL was associated with a 
reduction in prostate cancer mortality for men age 55 to 69 years 
when compared to the control arm (not screened)
biopsy 
• consider factors that lead to an increased PSA including prostate 
volume, age, and inflammation rather than using an absolute level to 
determine the need for a prostate biopsy 
• PSA is not a dichotomous test but rather a test that indicates the risk 
of a harmful cancer over a continuum. 
• postpone and/or avoiding a prostate biopsy in a man with a large 
prostate 
in the older male especially if in less than excellent health, and in the 
setting of a suspicion of prostatic inflammation, postpone/avoid biopsy 
even at PSA levels exceeding 3-4ng/mL
Be wise thankyou

More Related Content

What's hot

PSA test accuracy
PSA test accuracyPSA test accuracy
PSA test accuracyGaetan Lion
 
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista LemaireProstate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista LemaireNiela Valdez
 
An introduction to prostate cancer diagnosis
An introduction to prostate cancer diagnosisAn introduction to prostate cancer diagnosis
An introduction to prostate cancer diagnosisCatherine Holborn
 
Point counterpoint in PCa screening
Point counterpoint in PCa screeningPoint counterpoint in PCa screening
Point counterpoint in PCa screeningPatricia Khashayar
 
Prostate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, HaematuriaProstate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, HaematuriaMarc Laniado
 
Biomarkers of prostate cancer with staging
Biomarkers of prostate cancer with stagingBiomarkers of prostate cancer with staging
Biomarkers of prostate cancer with stagingroysudip900
 
Screening for carcinoma prostate
Screening for carcinoma prostateScreening for carcinoma prostate
Screening for carcinoma prostatePrakash Hs
 
Screening for prostate cancer 2018
Screening for prostate cancer 2018Screening for prostate cancer 2018
Screening for prostate cancer 2018Robert J Miller MD
 
Psa guideline exercise
Psa guideline exercisePsa guideline exercise
Psa guideline exerciseJohn Voss
 
PSA history and measurement
PSA history and measurementPSA history and measurement
PSA history and measurementAlexander Small
 
Prostate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queriesProstate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queriesMarc Laniado
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewZeena Nackerdien
 
The 4Kscore® blood test for risk of aggressive prostate cancer
The 4Kscore® blood test for  risk of aggressive prostate cancerThe 4Kscore® blood test for  risk of aggressive prostate cancer
The 4Kscore® blood test for risk of aggressive prostate cancerOPKO Labs
 

What's hot (20)

PSA test accuracy
PSA test accuracyPSA test accuracy
PSA test accuracy
 
Prostate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista LemaireProstate cancer - Vincent Batista Lemaire
Prostate cancer - Vincent Batista Lemaire
 
An introduction to prostate cancer diagnosis
An introduction to prostate cancer diagnosisAn introduction to prostate cancer diagnosis
An introduction to prostate cancer diagnosis
 
Prostate specific antigen
Prostate specific antigenProstate specific antigen
Prostate specific antigen
 
Point counterpoint in PCa screening
Point counterpoint in PCa screeningPoint counterpoint in PCa screening
Point counterpoint in PCa screening
 
Prostate cancer - PSA and PSA kinetics
Prostate cancer - PSA and PSA kineticsProstate cancer - PSA and PSA kinetics
Prostate cancer - PSA and PSA kinetics
 
Prostate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, HaematuriaProstate cancer detection, UroLifts, Haematuria
Prostate cancer detection, UroLifts, Haematuria
 
Biomarkers of prostate cancer with staging
Biomarkers of prostate cancer with stagingBiomarkers of prostate cancer with staging
Biomarkers of prostate cancer with staging
 
Prostate cancer (screening)
Prostate cancer (screening)Prostate cancer (screening)
Prostate cancer (screening)
 
Screening for carcinoma prostate
Screening for carcinoma prostateScreening for carcinoma prostate
Screening for carcinoma prostate
 
Screening for prostate cancer 2018
Screening for prostate cancer 2018Screening for prostate cancer 2018
Screening for prostate cancer 2018
 
Psa guideline exercise
Psa guideline exercisePsa guideline exercise
Psa guideline exercise
 
CANSA Men's health - Prostate Cancer - 2014
CANSA Men's health - Prostate Cancer - 2014CANSA Men's health - Prostate Cancer - 2014
CANSA Men's health - Prostate Cancer - 2014
 
PSA history and measurement
PSA history and measurementPSA history and measurement
PSA history and measurement
 
Psa
PsaPsa
Psa
 
Prostrate cancer
Prostrate cancerProstrate cancer
Prostrate cancer
 
Prostate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queriesProstate MDT workshop 16 nov 17 queries
Prostate MDT workshop 16 nov 17 queries
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overview
 
The 4Kscore® blood test for risk of aggressive prostate cancer
The 4Kscore® blood test for  risk of aggressive prostate cancerThe 4Kscore® blood test for  risk of aggressive prostate cancer
The 4Kscore® blood test for risk of aggressive prostate cancer
 
PIVOT
PIVOTPIVOT
PIVOT
 

Similar to Pros and cons of prostate cancer screening by mungai ngugi

Follow up of prostatectomy versus
Follow up of prostatectomy versusFollow up of prostatectomy versus
Follow up of prostatectomy versusPriyanka Malekar
 
Approach to a case of localized prostate cancer
Approach to a case of localized prostate cancerApproach to a case of localized prostate cancer
Approach to a case of localized prostate cancerDr Santosh Kumaraswamy
 
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00   Prostate Cancer Screening in the Post-USPSTF Era_0.pptxMon 8-00   Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptxRonitEnterprises
 
Carcinoma Prostate – Recent Advances
Carcinoma Prostate – Recent AdvancesCarcinoma Prostate – Recent Advances
Carcinoma Prostate – Recent AdvancesRobal Lacoul
 
Ca Prostate mgt.pptx
Ca Prostate mgt.pptxCa Prostate mgt.pptx
Ca Prostate mgt.pptxsarojsms
 
Prostate2013 130412164034-phpapp01
Prostate2013 130412164034-phpapp01Prostate2013 130412164034-phpapp01
Prostate2013 130412164034-phpapp01zonmbie24456
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptMusaibMushtaq
 
Prostate Cancer, EAU Guidelines.pptx
Prostate Cancer, EAU Guidelines.pptxProstate Cancer, EAU Guidelines.pptx
Prostate Cancer, EAU Guidelines.pptxDrSiyal
 
Cancer Screening in adults original.pptx
Cancer Screening in adults original.pptxCancer Screening in adults original.pptx
Cancer Screening in adults original.pptxSrikarBharadwaj3
 
Prostate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminarProstate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminarHarshaR35
 
benign prostatic hyperplasia by dr.bagasi
benign prostatic hyperplasia by dr.bagasibenign prostatic hyperplasia by dr.bagasi
benign prostatic hyperplasia by dr.bagasiAbdulaziz Bagasi
 
Case Study: Low Risk Prostate Cancer
Case Study: Low Risk Prostate CancerCase Study: Low Risk Prostate Cancer
Case Study: Low Risk Prostate CancerAli Bagheri
 

Similar to Pros and cons of prostate cancer screening by mungai ngugi (20)

Follow up of prostatectomy versus
Follow up of prostatectomy versusFollow up of prostatectomy versus
Follow up of prostatectomy versus
 
Approach to a case of localized prostate cancer
Approach to a case of localized prostate cancerApproach to a case of localized prostate cancer
Approach to a case of localized prostate cancer
 
pca screening.pdf
pca screening.pdfpca screening.pdf
pca screening.pdf
 
Prostate Cancer.pptx
Prostate Cancer.pptxProstate Cancer.pptx
Prostate Cancer.pptx
 
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00   Prostate Cancer Screening in the Post-USPSTF Era_0.pptxMon 8-00   Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
 
Repeat PSA testing
Repeat PSA testing Repeat PSA testing
Repeat PSA testing
 
Carcinoma Prostate – Recent Advances
Carcinoma Prostate – Recent AdvancesCarcinoma Prostate – Recent Advances
Carcinoma Prostate – Recent Advances
 
Ca Prostate mgt.pptx
Ca Prostate mgt.pptxCa Prostate mgt.pptx
Ca Prostate mgt.pptx
 
Prostate2013 130412164034-phpapp01
Prostate2013 130412164034-phpapp01Prostate2013 130412164034-phpapp01
Prostate2013 130412164034-phpapp01
 
Module 5 Dr Scholz-Screening&Biopsy
Module 5 Dr Scholz-Screening&BiopsyModule 5 Dr Scholz-Screening&Biopsy
Module 5 Dr Scholz-Screening&Biopsy
 
screening
screeningscreening
screening
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
 
Prostate Cancer, EAU Guidelines.pptx
Prostate Cancer, EAU Guidelines.pptxProstate Cancer, EAU Guidelines.pptx
Prostate Cancer, EAU Guidelines.pptx
 
Prostate Cancer 2013
Prostate Cancer 2013Prostate Cancer 2013
Prostate Cancer 2013
 
Cancer Screening in adults original.pptx
Cancer Screening in adults original.pptxCancer Screening in adults original.pptx
Cancer Screening in adults original.pptx
 
Prostate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminarProstate cancer molecular bio markers seminar
Prostate cancer molecular bio markers seminar
 
benign prostatic hyperplasia by dr.bagasi
benign prostatic hyperplasia by dr.bagasibenign prostatic hyperplasia by dr.bagasi
benign prostatic hyperplasia by dr.bagasi
 
CANSA The Big 5 Cancers affecting Men in South Africa 2017
CANSA The Big 5 Cancers affecting Men in South Africa 2017CANSA The Big 5 Cancers affecting Men in South Africa 2017
CANSA The Big 5 Cancers affecting Men in South Africa 2017
 
Prostate cancer health talk
Prostate cancer  health talkProstate cancer  health talk
Prostate cancer health talk
 
Case Study: Low Risk Prostate Cancer
Case Study: Low Risk Prostate CancerCase Study: Low Risk Prostate Cancer
Case Study: Low Risk Prostate Cancer
 

More from Kesho Conference

Use of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoUse of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoKesho Conference
 
The making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesaThe making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesaKesho Conference
 
Texas cancer centre by jipsy contractors
Texas cancer centre by  jipsy contractorsTexas cancer centre by  jipsy contractors
Texas cancer centre by jipsy contractorsKesho Conference
 
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...Kesho Conference
 
Stamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayananStamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayananKesho Conference
 
Setting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesaSetting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesaKesho Conference
 
Predictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinyaPredictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinyaKesho Conference
 
Post operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peterPost operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peterKesho Conference
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruKesho Conference
 
Opportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wangaOpportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wangaKesho Conference
 
Opportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidinaOpportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidinaKesho Conference
 
Joining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongoJoining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongoKesho Conference
 
Iron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. mainaIron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. mainaKesho Conference
 
History of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesaHistory of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesaKesho Conference
 
Global oncology by david miller
Global oncology by david millerGlobal oncology by david miller
Global oncology by david millerKesho Conference
 
Ethnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdallaEthnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdallaKesho Conference
 
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushnyEpidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushnyKesho Conference
 
Electronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesaElectronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesaKesho Conference
 
Earlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamedEarlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamedKesho Conference
 
Current and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutalaCurrent and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutalaKesho Conference
 

More from Kesho Conference (20)

Use of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoUse of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodo
 
The making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesaThe making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesa
 
Texas cancer centre by jipsy contractors
Texas cancer centre by  jipsy contractorsTexas cancer centre by  jipsy contractors
Texas cancer centre by jipsy contractors
 
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
 
Stamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayananStamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayanan
 
Setting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesaSetting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesa
 
Predictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinyaPredictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinya
 
Post operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peterPost operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peter
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weru
 
Opportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wangaOpportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wanga
 
Opportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidinaOpportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidina
 
Joining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongoJoining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongo
 
Iron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. mainaIron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. maina
 
History of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesaHistory of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesa
 
Global oncology by david miller
Global oncology by david millerGlobal oncology by david miller
Global oncology by david miller
 
Ethnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdallaEthnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdalla
 
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushnyEpidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
 
Electronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesaElectronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesa
 
Earlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamedEarlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamed
 
Current and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutalaCurrent and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutala
 

Recently uploaded

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 

Recently uploaded (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 

Pros and cons of prostate cancer screening by mungai ngugi

  • 1. “Pros and cons of prostate cancer screening” . Mungai Ngugi Director East African kidney institute University of Nairobi
  • 2. Introduction DEFINITION early detection and screening for prostate cancer • detection of disease at an early, pre-symptomatic stage • The man would have no reason to seek medical care – • The intervention is referred to as secondary prevention • Distinct from detection of prostate cancer in symptomatic men,
  • 3. Introduction • Population or mass screening is defined as the examination of asymptomatic men (at risk). • It usually takes place as part of a trial or study and is initiated by the screener. • In contrast, early detection or opportunistic screening comprises individual case findings, which are initiated by the person being screened (patient) and/or his physician
  • 4. introduction • Prostate cancer mortality trends range widely from country to country in the industrialised world . • Decreased mortality rates due to PCa have occurred in the USA, Austria, UK, and France, while in Sweden the 5-year survival rate has increased from 1960 to 1988, probably due to increased diagnostic activity and greater detection of non-lethal tumours .
  • 5. introduction • The primary endpoint of both types of screening has two aspects: • 1.Reduction in mortality from PCa. The goal is not to detect more carcinomas, nor is survival the endpoint because survival is strongly influenced by lead-time from diagnosis. • 2.The quality of life is important as expressed by quality-of-life adjusted gain in life years.
  • 6. introduction The reduced mortality seen recently in the USA is often attributed to the widely adopted aggressive screening policy, but there is still no absolute proof that prostate-specific antigen (PSA) screening reduces mortality due to PCa
  • 7. U.S. Preventive Services Task Force (USPSTF): • Although the USPSTF DISCOURAGES the use of screening tests for which the benefits do not outweigh the harms in the target population, it recognizes the common use of PSA screening in practice today and understands that some men will continue to request screening and some physicians will continue to offer it
  • 8. Potential Harms Related to Screening and Diagnostic Procedures • Convincing evidence demonstrates that the prostate-specific antigen (PSA) test often produces false-positive results • approximately 80% of positive PSA test results are false-positive when cut offs between 2.5 and 4.0 μg/L are used. • There is adequate evidence that false-positive PSA test results are associated with negative psychological effects, including persistent worry about prostate cancer • Men who have a false-positive test result are more likely to have additional testing, including 1 or more biopsies, in the following year than those who have a negative test result
  • 9. Harm USPSTF • one third of men who have prostate biopsy experience pain, fever, bleeding, infection, transient urinary difficulties, or other issues requiring clinician follow-up that the men consider a "moderate or major problem"; • approximately 1% require hospitalization.
  • 10. Harms Related to Treatment of Screen- Detected Cancer USPSTF • 90% of men with PSA-detected prostate cancer in the United States have early treatment with surgery, radiation, or androgen deprivation therapy • evidence shows that up to 5 in 1000 men will die within 1 month of prostate cancer surgery and between 10 and 70 men will have serious complications but survive. • Radiotherapy and surgery result in long-term adverse effects, including urinary incontinence and erectile dysfunction in at least 200 to 300 of 1000 men treated with these therapies. • Radiotherapy is also associated with bowel dysfunction.
  • 11. Harms Related to Treatment of Screen- Detected Cancer USPSTF • evidence shows that androgen deprivation therapy for localized prostate cancer is associated with erectile dysfunction (in approximately 400 of 1000 men treated), as well as gynecomastia and hot flashes.
  • 12. AUA • recommends against PSA screening in men under age 40 years. • does not recommend routine screening in men between ages 40 to 54 years at average risk • For ages 55 to 69 years the decision to undergo PSA screening involves weighing the benefits of preventing prostate cancer mortality in 1 man for every 1,000 men screened over a decade against the known potential harms associated with screening and treatment. • strongly recommends shared decision-making for men age 55 to 69 years that are considering PSA screening, and proceeding based on a man's values and preferences
  • 13. SCREENING • To reduce the harms of screening, a routine screening interval of two years or more may be preferred over annual screening in those men who have participated in shared decision-making and decided on screening. As compared to annual screening, it is expected that screening intervals of two years preserve the majority of the benefits and reduce overdiagnosis and false positives
  • 14. AUA • Since the advent of PSA screening, the incidence of patients presenting with advanced prostate cancer has declined remarkably and death rates from prostate cancer as reported in the National Cancer Database have declined at the rate of 1% per year since 1990. • Other data indicate similar declines in prostate cancer related mortality in the US. • THE DEGREE TO WHICH THIS IS ATTRIBUTABLE TO PSA SCREENING IS HIGHLY CONTROVERSIAL EVEN THOUGH IT IS TEMPORALLY LINKED WITH THE INTRODUCTION OF PSA-BASED SCREENING.
  • 15. AUA • does not recommend routine PSA screening in men age 70+ years or any man with less than a 10 to 15 year life expectancy • recommends against PSA screening in men under age 40 years. • In this age group there is a low prevalence of clinically detectable prostate cancer • no evidence demonstrating benefit of screening in <40 and there is likelihood of the same harms of screening as in other age groups. • does not recommend routine screening in men between ages 40 to 54 years at average risk of prostate cancer
  • 16. AUA guidelines • recommends screening with limited confidence in the target group age 55 to 69 years • This age range represents the group with the highest quality evidence of benefit. • There is potential for harm, and for this reason recommends shared decision making prior to screening decisions • The AUA used as evidence six trials-Stockholm, Norrkoping, Quebec, ERSPC, Goteborg and PLCO trials • The trials included men age 45 to 80 years, but only the Quebec trial informs about men below age 50 and above age 74 years.
  • 17. PSA • None of the studies were designed to estimate if PSA screening influences overall mortality
  • 18. AUA guidelines • For men younger than age 55 years at higher risk (e.g. positive family history or African American race), decisions regarding prostate cancer screening should be individualized. • For men ages 55 to 69 years the decision to undergo PSA screening involves weighing the benefits of preventing prostate cancer mortality in 1 man for every 1,000 men screened over a decade against the known potential harms associated with screening and treatment. • AUA recommends shared decision-making for men age 55 to 69 years that are considering PSA screening, and proceeding based on a man's values and preferences
  • 19. AUA guidelines • To reduce the harms of screening, a routine screening interval of two years or more may be preferred over annual screening in those men who have participated in shared decision-making and decided on screening. • screening intervals of two years preserve the majority of the benefits and reduces overdiagnosis and false positives • Does not recommend routine PSA screening in men age 70+ years or any man with less than a 10 to 15 year life expectancy
  • 20. Mortality outcomes Prostate cancer mortality sourrce Relative risk Absolute effect 1RCT ERSPC 162243 Age 55-69 psa every four years 0.8(0.65-0.98) 1 death /1000 men screaned 1 rctPCLO 79693 Age 55-74 annual PSA screaning for 6 yrs and DRE annually for four ysa 1.14(0.76-1.70) >1 death -1 death -1 death per 1000 men sreaned
  • 21. Harm outcome Minor (hematuria/ hematospermia) 20-50% 20-50% (first time sextant biopsy, Netherland site, ERSPC) 24-45% (ERSPC, Rotterdam) Composite medical complications (infection, bleeding, urinary difficulties) 68/10,000 PLCO33
  • 22. Harm outcome false positive Adverse event estimate Data source evidence False +ve tests 75.9% Proportion of men psa>3ngms/ml and no cancer on subsequent biopsy ESPRC Moderate to high 12% Cummulative risk of at least 1 false positive after four rounds of testing every 4 years ERSPC 13% risk of undergoing at least 1 +positive biopsy (psa>4) after four rounds of annual testing PCLO 5.5% Risk of undergoing
  • 23. Harm outcome -overdiagnosis 66% Cases overdiagnosed as a fraction of screan detected cases ESRPC 23-42% Cases overdiagnosed as a fraction of screan detected cases SEER-9 1987-2000
  • 24. Harm outcome leadtime 5.4-6.9 years Average time by which screaning advances diagnosis among cases who would have been diagnosed during their lifetime in the absence of screaning
  • 25. screening • Introduction of PSA-based prostate cancer screening was followed by subsequent dramatic reductions in prostate cancer mortality. • in the US following the introduction of widespread PSA screening in the late 1980's, there ensued a ~70% increase in prostate cancer incidence. • Despite steadily rising prostate cancer mortality throughout the 1970s and 1980s, several years after the introduction of PSA screening, mortality rates began to decline. • By 2008, mortality rates had fallen nearly 40% relative to their highs in the early 1990s Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10.
  • 26. US vs uk • In the US PSA screening became widespread in the late 1980s and early 1990s. • PSA screening was rarely performed in the UK and to this day remains lower than 10% of the population. • Prostate cancer death rates in the US began to decline in the early 1990s and by 2009 had dropped by more than 40% since their peak in the early 1990s • The peak in incidence in the US was followed by a decline (36%) in mortality starting several years later Collin SM, Martin RM, Metcalfe C et al: Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445.
  • 27. US vs UK • Though mortality rates also declined in the UK, the decline was much more modest (only 12%). Indeed, since 1994 prostate cancer mortality rates have declined four times faster in the US compared to the UK Howlader N, Noone AM, Krapcho M et al: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web
  • 28. psa • Almost all of the randomized studies that have evaluated PSA based screening for prostate cancer have demonstrated a benefit in terms of lower stage and grade of cancer at diagnosis. • Several studies have also revealed a significant reduction in prostate cancer specific mortality rates attributable to PSA based screening for prostate cancer
  • 29. psa • PSA screening yields survival benefits that have contributed, to some extent, to the dramatic and sustained drop in prostate cancer death rates in the USA. • Second, PSA screening advances prostate cancer diagnosis by five to six years on average.
  • 30. Psa • Approximately one in four screen-detected cases reflects overdiagnosis. • Strategies that screen less frequently than every year, and even less frequently for men with low PSA levels, are likely to be of value in reducing costs and harms while preserving most of the potential benefit of PSA-based screening
  • 31. Psa developed countries • Since the advent of PSA screening, the incidence of patients presenting with advanced prostate cancer has declined remarkably and death rates from prostate cancer as reported in the National Cancer Database have declined at the rate of 1% per year since 1990. • Other data indicate similar declines in prostate cancer related mortality in the US. • The degree to which this is attributable to PSA screening is highly controversial even though it is temporally linked with the introduction of PSA-based screening
  • 32. Increasing the ratio of benefit to harm • Screening for cancer in asymptomatic individuals, including prostate cancer, involves a tradeoff of benefit and harm • Through a decade, the absolute benefits of prostate cancer screening are modest for men age 55 to 69 years, and the harms are substantial • Over a lifetime the benefits increase but so do the harms. • The ratio of benefit to harm can be improved by looking at the health and age status of the individual and his preferences
  • 33. Increacing benefit of screening • The strongest evidence of benefit for PSA screening for early diagnosis of prostate cancer is in the age group 55 to 69 years17 since this is the group studied in randomized trials • Thus, targeting of men age 55 to 69 years, after a risk benefit discussion, represents one approach to screening that is based on best evidence
  • 34. <40 years • For men below age 40 years, AUA recommends against PSA-based screening. • The low prevalence of disease in men below age 40 years means that even in the best case of screening benefit in this age group, the incremental number of lives save by screening this age group is likely to be very small
  • 35. 40-54yrs • Men age 40 to 54 years often undergo PSA-based screening. However, as compared to initiating screening at age 50 years, it was estimated that screening beginning at age 40 years would result in the prevention of <1 prostate cancer death per 1,000 men. • Given that 99% of deaths from prostate cancer occur above age 54 years, the screening average risk men below age 55 years should not be routine. Howard K, Barratt A, Mann GJ et al: A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009; 169: 1603.
  • 36. <55 • For men younger than age 55 years at higher risk (e.g. positive family history or African American race), decisions regarding prostate cancer screening should be individualized based on personal preferences and an informed discussion regarding the uncertainty of benefit and the associated harms of screening.
  • 37. >70yrs • Men age 70+ years have a high prevalence of prostate cancer but also have a greater risk of competing diseases and overdiagnosis when compared to younger men • ERSPC randomized trial of screening, there was no indication for a mortality reduction among men age 70 years or older by psa screening • given the lack of direct evidence for a benefit of screening beyond age 70 years, and especially beyond age 74 years, routine screening in this age group is dicouraged Albertsen PC, Moore DF, Shih W et al: Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 133594, Schroder FH, Hugosson J, Roobol MJ et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981.
  • 38. Fit men • Some men with high risk aggressive prostate cancers with a life expectancy less than a decade, may benefit from the diagnosis and treatment of their disease. Thus, the goal should be to identify these men while avoiding the associated overdiagnosis and over treatment of those with lower risk disease that occurs with opportunistic screening Wilt TJ, Brawer MK, Jones KM et al: Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203.
  • 39. Testing Frequency • There is evidence to suggest that annual screening is not likely to produce significant incremental benefits when compared with an inter-screening interval of two years • The PLCO trial compared annual screening with opportunistic screening in the US population, which corresponded to screening on average every two years. • Prostate cancer mortality rates were similar in the two groups through 13 years of follow-up. 20
  • 40. Biopsy Trigger • There is no PSA level below which a man can be informed that prostate cancer does not exist. • the risk of prostate cancer, and that of high grade disease, is continuous as PSA increases • In the intervention (screened) arm of the ERSPC randomized screening trial, a PSA trigger of 3ng/mL was associated with a reduction in prostate cancer mortality for men age 55 to 69 years when compared to the control arm (not screened)
  • 41. biopsy • consider factors that lead to an increased PSA including prostate volume, age, and inflammation rather than using an absolute level to determine the need for a prostate biopsy • PSA is not a dichotomous test but rather a test that indicates the risk of a harmful cancer over a continuum. • postpone and/or avoiding a prostate biopsy in a man with a large prostate in the older male especially if in less than excellent health, and in the setting of a suspicion of prostatic inflammation, postpone/avoid biopsy even at PSA levels exceeding 3-4ng/mL